To cite: Zhang L, Liu W, Liu D, et al. Epidemiological and clinical features of human metapneumovirus in hospitalised paediatric patients with acute respiratory illness: a cross-sectional study in Southern China, from 2013 to 2016. BMJ Open 2018;8:e019308. doi:10.1136/bmjopen-2017-019308

ABSTRACT

Objectives Human metapneumovirus (HMPV) is one of the most important respiratory viral pathogens affecting infants and children worldwide. Our study describes the epidemiological and clinical characteristics of HMPV present in patients hospitalised with acute respiratory illness (ARI) in Guangzhou, Southern China.

Study design A cross-sectional study.

Setting Two tertiary hospitals in Guangzhou.

Participants and methods Throat swabs were collected over a 3-year period from 5133 paediatric patients ≤14 years hospitalised with ARI. Patients who are HMPV positive with clinical presentations (101/103) were recorded for further analysis.

Results Of the 5133 patients included in the study, 103 (2.0%) were positive for HMPV. HMPV was more prevalent in children ≤5 years (2.2%, 98/4399) compared with older children (≥5–14 years) (0.7%, 5/734) (P=0.004). Two seasonal HMPV peaks were observed each year and mainly occurred in spring and early summer. Overall, 18.4% (19/103) of patients who are HMPV positive were codetected with other pathogens, most frequently respiratory syncytial virus (36.8%, 7/19). Patients who are HMPV positive presented with a wide spectrum of clinical features, including cough (100.0%, 101/101), abnormal pulmonary breath sound (91.1%, 92/101), fever (88.1%, 89/101), expectoration (77.2%, 78/101), coryza (50.5%, 51/101) and wheezing (46.5%, 47/101). The main diagnosis of patients who are HMPV positive was bronchopneumonia (66.7%, 56/84). Fever (≥38°C) (91.6%, 76/83) was detected more often in patients with only HMPV detected than in patients with HMPV plus other pathogen(s) detected (72.2%, 13/18) (P=0.037), whereas diarrhoeas was more common in patients with HMPV plus other pathogen(s) detected (22.2%, 4/18), compared with patients with HMPV only (3.6%, 3/83) (P<0.01).

Conclusions HMPV is an important respiratory pathogen in children with ARI in Guangzhou, particularly in children ≤5 years old. HMPV has a seasonal variation. Bronchopneumonia is a major diagnosis in patients who are HMPV positive.

Strengths and limitations of this study

▸ Five thousand one hundred and thirty-three patients hospitalised with acute respiratory illness at two large municipal tertiary hospitals (hospital beds >1000) were enrolled on the study over 3 years.
▸ Patients aged from 1 day to 14 years old were tested for human metapneumovirus (HMPV) using TaqMan real-time PCR.
▸ Clinical characteristics of patients with HMPV positive were recorded.
▸ There was incomplete HMPV copathogen detection, because bacterial pathogens were not detected for patients who are HMPV positive.
▸ The clinical characteristics of patients who are HMPV negative and outcome data (discharge/death) for the patients who are HMPV positive were not collected for further analysis, limiting our understanding of this pathogen.

INTRODUCTION

Human metapneumovirus (HMPV) is a non-segmented, negative-sense single-stranded RNA virus, which belongs to the Paramyxoviridae family. HMPV was first discovered in 2001 in the Netherlands, after being isolated from a paediatric patient with acute respiratory illness (ARI). Since then, HMPV has been associated with acute respiratory disease in individuals of all ages worldwide. Children, elderly and immunocompromised adults are most at risk of contracting the virus. Children younger than 5 years of age seem to be particularly susceptible to HMPV. Previous studies, which were mainly conducted in developed countries, have revealed that approximately 2.5%–11.3% of respiratory samples were...
positive for HMPV in children ≤5 years, and 90% of individuals were seropositive for HMPV by 5 years of age.13 HMPV causes a variety of clinical symptoms ranging from a mild upper respiratory tract infection (URI) to life-threatening lower respiratory tract infection (LRTI).14–16 However, to date, there is no effective vaccine or specific medication either for the prevention or treatment of HMPV infection. Consequently, it is imperative to conduct more studies, especially in low/middle-income countries, to understand this pathogen in different areas and populations.

In this study, we investigated the epidemiological and clinical features of HMPV in pediatric patients, from July 2013 to June 2016. The findings of this study will help understand the distribution of HMPV in a subtropical region. Our results also provide a valuable insight into the clinical features of HMPV, which will improve early clinical diagnosis.

**METHODS**

**Study design and respiratory sample collection**

We conducted a cross-sectional study at two tertiary hospitals in Guangzhou, Southern China. Throat swab samples (n=5133), from pediatric patients (≤14 years) hospitalised with ARI, were collected at two hospitals between July 2013 and June 2016. ARI was defined as an illness that presented with at least two of the following clinical presentations: cough, nasal obstruction, coryza, sneeze and dyspnoea during the previous week. Patients, who were diagnosed with pneumonia by chest radiography during the previous week, were also included in the study, even if they did not show the clinical features described above. Some patients, who had been cured and discharged some time ago and readmitted because of new episodes of ARI, were assigned to several clinical presentation groups. Patients with incomplete clinical data were excluded from this analysis. Increased lung markings, bronchopneumonia, pneumonia and bronchiolitis were diagnosed by chest radiography. Abnormal pulmonary breath sounds included phlegmatic, wheezy, bubbling and moist rales. Other clinical symptoms were identified by a general medical examination and clinical descriptions, as previously reported.19

**Real-time PCR for HMPV detection**

RNA was extracted from the throat swabs samples with the QIAamp Viral RNA Mini Kit (Qiagen, Shanghai, China), according to the manufacturer’s protocols. HMPV was identified by using TaqMan real-time PCR assays, as previously reported, using kits from Guangzhou HuYanSuo Medical Technology according to the manufacturer’s protocols. In brief, 50 µL RNA were extracted from a 200 µL sample, and real-time PCR was conducted using 25 µL reaction mix, containing Moloney murine leukemia virus reverse transcriptase, Taq polymerase and 5 µL extracted RNA. Cycling conditions included an initial reverse transcription at 55°C for 10 min, incubation at 94°C for 2 min, followed by 40 cycles of 94°C for 10s and 55°C for 35 s (ABI-7500 real-time PCR instrument; Life Technologies, Singapore).

**Detection of common respiratory pathogens in patients who are HMPV positive**

HMPV-positive samples were tested simultaneously using TaqMan real-time PCR assays for the following 17 respiratory pathogens: respiratory syncytial virus (RSV); parainfluenza virus types 1–4 (PIV1–4); influenza A and B viruses (InfA, InfB); adeno virus (ADV); enterovirus (EV); human coronaviruses (HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1); human rhinovirus (HRV); human bocavirus (HBoV); Mycoplasma pneumoniae (MP); and Chlamydo phila pneumoniae (CP). The testing procedure was conducted using kits from Guangzhou HuYanSuo Medical Technology as previously described.18

**Statistical analysis**

All statistical analyses were performed with SPSS statistical software (V.19.0). To compare categorical data, X² and Fisher’s exact tests were used, as appropriate. All tests were two-tailed, and P<0.05 was considered statistically significant.

**RESULTS**

**Detection of HMPV from patients with ARI**

In total, 5133 paediatric patients, ranging from 1 day to 14 years old were enrolled in this study. The male to female ratio was 1.75 (3269:1864) and the median age was 33 months (IQR 9–48 months). Of the 5133 patients, 103 (2.0%) were positive for HMPV. The male to female ratio was 1.86:1 (67:36) in patients who are HMPV positive and as having gastrointestinal illness. Some patients were assigned to several clinical presentation groups. Patients with incomplete clinical data were excluded from this analysis. Increased lung markings, bronchopneumonia, pneumonia and bronchiolitis were diagnosed by chest radiography. Abnormal pulmonary breath sounds included phlegmatic, wheezy, bubbling and moist rales. Other clinical symptoms were identified by a general medical examination and clinical descriptions, as previously reported.19
1.75:1 (3202:1828) in patients who are HMPV negative (P=0.771). The median age in months of patients who are HMPV positive was 23.5 months (IQR 10–36 months).

Codetection with common respiratory pathogens in patients who are HMPV positive

We also tested HMPV-positive samples for 17 common respiratory pathogens. Of the 103 patients who are HMPV positive, 84 (81.6%) patients had only HMPV detection and 19 (18.4%) patients had HMPV plus other pathogen(s) detected. Nine out of 17 respiratory pathogens (52.9%) were detected and the most common co-detection pathogens were RSV (36.8%, 7/19), HCoV-OC43 (15.8%, 3/19), MP (15.8%, 3/19) and HBoV (15.8%, 3/19) (table 1). The male to female ratio was 2:1 (56:28) in patients with only HMPV detected and 1.38:1 (11:8) in patients with HMPV plus other pathogen(s) detected (P=0.469).

Age distribution of patients who are HMPV positive

Overall, there was a significant difference in HMPV prevalence between patients >5–14 years (0.7%, 5/734) and those ≤5 years (2.2%, 98/4399) (P=0.004). The patients were divided into six age groups: 0–3 months, >3–6 months, >6–12 months, >1–2 years, >2–5 years and >5–14 years. The distribution of HMPV prevalence between these age groups was significantly different (P=0.03), and children >1–2 years had the highest prevalence (2.8%, 21/752) (figure 1).

Table 1 Distribution of copathogens in 19 patients who are HMPV positive

| Copathogens* | No of patients |
|-------------|----------------|
| RSV/HMPV    | 4              |
| HCoV-OC43/HMPV | 3            |
| ADV/HMPV    | 2              |
| HRV/HMPV    | 2              |
| MP/HMPV     | 1              |
| PIV2/HMPV   | 1              |
| PIV3/HMPV   | 1              |
| RSV/MP/HMPV | 1              |
| RSV/InfA/HMPV | 1            |
| RSV/HBoV/HMPV | 1           |
| MP/HBoV/HMPV | 1            |
| InfA/HBoV/HMPV | 1           |

*Patients who are HMPV positive were tested for 17 common respiratory pathogens. Influenza B viruses, parainfluenza virus types 1 and 4, enterovirus, human coronaviruses-HKU1, human coronaviruses-229E, human coronaviruses-NL63 and Chlamydia pneumoniae were not detected.

ADV, adenovirus; HBoV, human bocavirus; HCoV, human coronaviruses; HMPV, human metapneumovirus; HRV, human rhinovirus; InfA, influenza A virus; MP, Mycoplasma pneumoniae; PIV, parainfluenza virus; RSV, respiratory syncytial virus.

Seasonal distribution of HMPV

Over the 3-year study period, the prevalence of HMPV peaked twice every year (figure 2). Large peaks occurred in March 2014 (8%, 16/200), May 2015 (7.6%, 8/105) and February 2016 (8.7%, 9/103). Small peaks occurred in November 2014 (1.7%, 2/121), September 2015 (2.8%, 2/72) and May 2016 (1.5%, 2/135) (figure 2).

Clinical presentation of patients who are HMPV positive

We analysed the clinical presentation of 101 of the 103 (98.1%) patients who are HMPV positive, the other two patients were excluded from this analysis because of incomplete clinical data. The main clinical features of patients who are HMPV positive included cough (100.0%, 101/101), abnormal pulmonary breath sound (91.1%, 92/101), fever (88.1%, 89/101), expectoration (77.2%, 78/101), coryza (50.5%, 51/101) and wheezing (46.5%, 47/101).
47/101). Of 84 with a chest radiography, 56 (66.7%) were diagnosed with bronchopneumonia, 11 (13.1%) were pneumonia and 8 (9.5%) were bronchiolitis (Table 2). We also compared the clinical features of patients with only HMPV detected and those of the patients with HMPV plus other pathogen(s) detected. Fever and diarrhoea were the two symptoms that were identified as statistically different between these two groups. A fever (≥38°C) was seen more common in patients with only HMPV detected (91.6%, 76/83), compared with 72.2% (13/18) in patients with HMPV plus other pathogen(s) detected (P=0.037). Conversely, diarrhoea appeared more often in patients with HMPV plus other pathogen(s) detected (22.2%, 4/18) than in the patients with only HMPV detected (3.6%, 3/83) (P=0.018) (Table 2).

**DISCUSSION**

Viruses are the most frequent cause of respiratory infections. HMPV has been recognised as an important cause of ARI since its discovery in 2001. A previous study reported HMPV was responsible for approximately 5%–10% of hospitalisations in children suffering from ARI, creating a considerable clinical and economic burden worldwide. HMPV detection rates vary according to geographic location, and the incidence of HMPV may show seasonal or annual patterns in the same area. In previous studies, HMPV was detected in approximately 1%–17% of ARI cases. In this 3-year study, 103 of 5133 (2.0%) patients were positive for HMPV, which is similar to previous reports of HMPV in patients with ARI in Southern China and Japan.
Children under 5 years of age are most susceptible to HMPV infection, and those younger than 2 years of age are at the greatest risk of developing serious conditions. In our study, HMPV-positive cases appeared more frequently in patients ≤5 years old (2.2%, 98/4399) than in patients >5 years old (0.7%, 5/734) (P=0.004), which is consistent with many previous studies. Specifically, HMPV prevalence was highest in children 1–2 years (2.8%, 21/752). This may be explained by the immunity against HMPV, which is passed down from mother to child, gradually subsiding over time. Moreover, children were more contact with outside world as they grew older. Therefore, children of this age need more attention to prevent HMPV infection. Moreover, our findings suggested no difference in risk between sex, there was no significant difference in the HMPV prevalence between male and female patients (P=0.771), which is consistent with previous studies.

HMPV has a typical seasonal distribution. HMPV activity is largely affected by different local climate factors. The prevalence of HMPV in temperate climates peaks at the end of winter or in early spring. In our study, seasonal peaks of HMPV were detected in February 2016, March 2014 and May 2015. This finding indicates that HMPV circulates primarily during the spring and early summer in Guangzhou, this pattern is similar to previous reports from other subtropical areas. Furthermore, we also found small peaks in November 2014, September 2015 and May 2016, the reason for this is unknown. It should be noted that the seasonal distribution of HMPV overlaps with RSV in this geographical area. Knowing the epidemiological characteristics of HMPV will help public health authorities and clinicians to improve strategies for controlling HMPV infection.

HMPV coinfection with other respiratory pathogens has been reported in many studies, including RSV, Infa, InfB, PIV, ADV, HBoV, HCoV, HRV, EV, MP and CP. In our study, most patients who are HMPV positive only had HMPV (81.6%, 84/103), and there was no significant difference in the HMPV prevalence according to sex between the patients with only HMPV detected and the patients with HMPV plus other pathogen(s) detected (P=0.469). The codetection rate was 18.4% (19/103), and RSV (36.8%, 7/19) was the most frequently codetected pathogen, which might be because of the overlapping seasonal distribution of these two pathogens. Codetection rates of HCoV-OC43, MP, HBoV, ADV, HRV, Infa, PIV2 and PIV3 were over 5%, suggesting a broad range of respiratory pathogens could coexist with HMPV in ARI paediatric patients.

HMPV most commonly causes URTI and LRTI in young children. The clinical manifestations of patients who are HMPV positive are similar to those of patients who are RSV positive, especially in young children. In previous studies, the most frequent diagnoses of children hospitalised with HMPV infection were pneumonitis and bronchiolitis. In some studies, bronchiolitis and recurrent wheezing/pneumonia were the main clinical diagnoses, while in other studies, bronchopneumonia, bronchiolitis and bronchial asthma exacerbation were the main clinical diagnoses. Our study showed that 66.7% (56/84), 9.5% (8/84) and 13.1% (11/84) of patients who are HMPV positive were diagnosed with bronchopneumonia, bronchiolitis and pneumonia by chest radiography, respectively. Of all the clinical features recorded, cough (100.0%, 101/101), abnormal pulmonary breath sound (91.1%, 92/101), fever (88.1%, 89/101), expectoration (77.2%, 78/101), coryza (50.5%, 51/101) and wheezing (46.5%, 47/101) occurred frequently in patients who are HMPV positive, similar to those reported previously.

Most of the patients who are HMPV positive had a fever (88.1%, 89/101); it appeared more frequently in patients with only HMPV detected than in the patients with HMPV plus other pathogen(s) detected (P=0.037). Diarrhoea was not a major symptom in patients who are HMPV positive (7.0%, 7/101), but it had a higher prevalence in patients with HMPV plus other pathogen(s) detected than in the patients with only HMPV detected (P=0.018), suggesting that diarrhoea is probably caused by other pathogens. No significant difference was found in the other clinical features between the patients with only HMPV detected and the patients with HMPV plus other pathogen(s) detected, similar to the results of a previous study.

In our study, RSV (36.8%, 7/19) was the most frequently codetected pathogen in patients who are HMPV positive. Whether HMPV/RSV coinfection is more severe than the respective monoinfection remains unclear. A previous study showed that children with HMPV/RSV coinfection were more likely to develop pneumonia; however, disease severity was not increased. Conversely, Semple et al reported that HMPV/RSV co-infection can cause more severe bronchiolitis in patients. In our study, no significant difference in the diagnosis of pneumonia was observed between the patients with only HMPV detected and the patients with HMPV plus other pathogen(s) detected. It has been confirmed that a history of prematurity, particular age groups, and the presence of chronic diseases increases the risk of severe LRTI among children infected with HMPV and RSV. Our study suggests that the clinical manifestations of HMPV infection are complex and diverse; our data will be helpful in the diagnosis of HMPV.

In this study, we analysed the epidemiological characteristics and clinical characteristics of HMPV in >5000 children with ARI in two tertiary hospitals in Guangzhou, which is an international metropolis and the most important political, economic and cultural centre in Southern China. Therefore, the results are not limited to two hospital cases, but also represent and reflect HMPV infection in children with ARI in South China and play a positive role in the prevention and diagnosis of HMPV infection in the area.

The study had some limitations. First, collection of data on symptoms and physical findings in infants and young children require experienced medical staff, patient’s
concerns. Our study highlights the importance of HMPV as an emerging respiratory pathogen in children with ARI in Guangzhou, Southern China.

CONCLUSIONS

HMPV is an important respiratory pathogen in children with ARI in Guangzhou, China, particularly in children under 5 years old. In future, our data can be used by public health authorities and clinicians to improve the management of HMPV infection in children.

Author affiliations

1State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China
2Department of Pediatrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China
3Department of Pediatrics, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of China

Acknowledgements We thank the study volunteers for their generous participation. We thank Yinying Zhou, Haiping Huang, Jing Zhang and Jing Ma for technical assistance. We thank Xiaofeng Li and Zhenghui Lin for paper polishing.

Contributors RZ, WL, LZ and DL designed the study. LZ, DL, WL, SQ, DX, XL and TL performed pathogen testing. DC and WT collected the clinical data. All authors participated in the data analysis. LZ, DL, RZ and WL drafted the manuscript. All authors read and approved the final version of this manuscript.

Funding This study was supported by The State Major Infectious Disease Research Program (RZ) (2017ZX10103011-003), National Natural Science Foundation of China (WKL) (31500143), Guangzhou Science and Technology Program key projects (RZ) (2017ZX10103011-003), National Natural Science Foundation of China (RZ) (201508020252).

Competing interests None declared.

Patient consent Parental/guardian consent obtained.

Ethics approval The study was approved by the First Affiliated Hospital of Guangzhou Medical University Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. van den Hoogen BG, Herfst S, Sprong L, et al. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 2004;10:658–66.
2. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001;7:719–24.
3. Boivin G, Abed Y, Pelletier G, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002;186:1330–4.
4. Falsky AR, Walsh EE. Viral pneumonia in older adults. Clin Infect Dis 2006;42:518–24.
5. Kahn JS. Epidemiology of human metapneumovirus. Clin Microbiol Rev 2008;19:546–57.
6. Davis CR, Stockman CM, Pavia AT, et al. Incidence, morbidity, and costs of human metapneumovirus infection in hospitalized children. J Pediatric Infect Dis Soc 2016;5:303–11.
7. Edwards KM, Zhu Y, Griffin MR, et al. Burden of human metapneumovirus infection in young children. N Engl J Med 2013;368:653–63.
8. Fouloungue V, Guyon G, Roudière M, et al. Human metapneumovirus infection in young children hospitalized with respiratory tract disease. Pediatr Infect Dis J 2006;25:354–9.
9. Heikkinen T, Osterback R, Peltola V, et al. Human metapneumovirus infections in children. Emerg Infect Dis 2008;14:101–6.
10. Nicholson KG, McNally T, Silverman M, et al. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 2008;26:102–8.
11. Sloots TP, Mackay IM, Bialasiewicz S, et al. Human metapneumovirus, Australia, 2001-2004. Emerg Infect Dis 2006;12:1263–6.
12. Williams JV, Edwards KM, Weinberg GA, et al. Population-based incidence of human metapneumovirus infection among hospitalized children. J Infect Dis 2010;201:1861–8.
13. Ebihara T, Endo R, Kikuta H, et al. Seroprevalence of human metapneumovirus in Japan. J Med Virol 2003;70:281–3.
14. Panda S, Mohakud NK, Pena L, et al. Human metapneumovirus: review of an important respiratory pathogen. Int J Infect Dis 2014;25:45–52.
15. Broor S, Bharaj P, Chahar HS. Human metapneumovirus: a new respiratory pathogen. J Biolog 2008;33:483–93.
16. Jain B, Singh AK, Dangi T, et al. High prevalence of human metapneumovirus subtype B in cases presenting as severe acute respiratory illness: an experience at tertiary care hospital. Clin Respir J 2014;8:225–33.
17. Liu WK, Liu Q, Chen DH, et al. Epidemiology and clinical presentation of the four human parainfluenza virus types. BMC Infect Dis 2013;13:28.
18. Liu WK, Chen DH, Liu Q, et al. Detection of human bocavirus from children and adults with acute respiratory tract illness in Guangzhou, southern China. BMC Infect Dis 2011;11:345.
19. Liu W, Chen D, Tari W, et al. Epidemiology and clinical presentations of respiratory syncytial virus subgroups A and B detected with multiplex real-time PCR. PLoS One 2016;11:e0165108.
20. Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002;2:25–32.
21. Esquivar C, Luchsinger V, de Oliveira DB, et al. Genetic variability of human metapneumovirus isolated from Chilean children, 2003-2004. J Med Virol 2009;81:340–4.
22. Garcia-Garcia ML, Calvo C, Rey C, et al. Human metapneumovirus infections in hospitalized children and comparison with other respiratory viruses. 2005-2014 prospective study. PLoS One 2017;12:e0173504.
23. Ljubin-Ster S, Savic RT, Djordjevic SP, et al. Detection of genetic lineages of human metapneumovirus in croatia during the winter season 2005/2006. J Med Virol 2008;80:1282–7.
24. McCracken JP, Arvelo W, Ortiz J, et al. Comparative epidemiology of human metapneumovirus- and respiratory syncytial virus-associated hospitalizations in Guatemala. Influenza Other Respir Viruses 2014;8:414–21.
25. Nor'e SS, Sam IC, Meahmed Fakri EF, et al. Phylogenetic analysis of human metapneumovirus among children with acute respiratory infections in Kuala Lumpur, Malaysia. Trop Biomed 2014;31:562–6.
26. Ordás J, Boga JA, Alvarez-Arugüelles M, et al. Role of metapneumovirus in viral respiratory infections in young children. J Clin Microbiol 2006;44:2729–42.
27. Rafieifar F, Yun Z, Orvell C. Epidemiologic characteristics and seasonal distribution of human metapneumovirus infections in five
epidemic seasons in Stockholm, Sweden, 2002-2006. J Med Virol 2008;80:1631–8.
28. Rodriguez PE, Adamo MP, Paglini MG, et al. Monoinfection of human metapneumovirus in Cordoba: first clinical and epidemiological research in children with respiratory infection in 2011. Rev Fac Cienc Med Univ Nac Cordoba 2016;73:170–5.
29. Zeng SZ, Xiao NG, Zhong LL, et al. Clinical features of human metapneumovirus genotypes in children with acute lower respiratory tract infection in Changsha, China. J Med Virol 2015;87:1839–45.
30. Zhu RN, Qian Y, Zhao LQ, et al. Characterization of human metapneumovirus from pediatric patients with acute respiratory infections in a 4-year period in Beijing, China. Chin Med J 2011;124:1623–8.
31. Cai XY, Wang Q, Lin GY, et al. Respiratory virus infections among children in South China. J Med Virol 2014;86:1249–55.
32. Matsuzaki Y, Itagaki T, Aibko C, et al. Clinical impact of human metapneumovirus genotypes and genotype-specific seroprevalence in Yamagata, Japan. J Med Virol 2008;80:1084–9.
33. Barbosa Ramirez J, Pulido Dominguez P, Rey Benito G, et al. Human respiratory syncytial virus and metapneumovirus in patients with acute respiratory infection in Colombia, 2000 - 2011. Rev Panam Salud Publica 2014;36:101–9.
34. Zhang C, Du LN, Zhang ZY, et al. Detection and genetic diversity of human metapneumovirus in hospitalized children with acute respiratory infections in Southwest China. J Clin Microbiol 2012;50:2714–9.
35. McAdam AJ, Hasenbein ME, Feldman HA, et al. Human metapneumovirus in children tested at a tertiary-care hospital. J Infect Dis 2004;190:20–6.
36. Boivin G, De Serres G, Côté S, et al. Human metapneumovirus infections in hospitalized children. Emerg Infect Dis 2003;9:634–40.
37. Maggi F, Pifferi M, Vattoroni M, et al. Human metapneumovirus associated with respiratory tract infections in a 3-year study of nasal swabs from infants in Italy. J Clin Microbiol 2003;41:2987–91.
38. van den Hoogen BG, van Doorsselaere J, Fockens JC, et al. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis 2003;188:1571–7.
39. Peiris JS, Tang VH, Chan KH, et al. Children with respiratory disease associated with metapneumovirus infection in Hong Kong. Emerg Infect Dis 2002;9:628–33.
40. Grensill J, McNamara PS, Dove W, et al. Human metapneumovirus in severe respiratory syndromic bronchiolitis. Emerg Infect Dis 2002;9:372–5.
41. Lin PY, Lin TY, Huang YC, et al. Human metapneumovirus and community-acquired pneumonia in children. Chang Gung Med J 2005;28:683–8.
42. Ghattas C, Mossad SB. Fatal human metapneumovirus and influenza B virus co-infection in an allogeneic hematopoietic stem cell transplant recipient. Transplant Infect Dis 2012;14:E41–5.
43. Fathima S, Lee BE, May-Hadford J, et al. Use of an innovative web-based laboratory surveillance platform to analyze mixed infections between human metapneumovirus (hMPV) and other respiratory viruses circulating in Alberta (AB), Canada (2009-2012). Viruses 2012;4:2754–65.
44. Kaida A, Kubo H, Goto K, et al. Co-infection of human metapneumovirus with adenovirus or respiratory syncytial virus among children in Japan. Microbiol Immunol 2007;51:679–83.
45. Pilger DA, Cantarelli VV, Amantea SL, et al. Detection of human bocavirus and human metapneumovirus by real-time PCR from patients with respiratory symptoms in Southern Brazil. Mem Inst Oswaldo Cruz 2011;106:58–60.
46. Esposito S, Daleno C, Prunotto G, et al. Impact of viral infections in children with community-acquired pneumonia: results of a study of 17 respiratory viruses. Influenza Other Respir Viruses 2013;7:19–26.
47. Kahn JS. Newly discovered respiratory viruses: significance and implications. Curr Opin Pharmacol 2007;7:478–83.
48. Wolf DG, Greenberg D, Kalkstein D, et al. Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young children. Pediatr Infect Dis J 2006;25:320–4.
49. Wiklesmann A, Schildgen O, Eis-Hubinger AM, et al. Human metapneumovirus infections cause similar symptoms and clinical severity as respiratory syncytial virus infections. Eur J Pediatr 2006;165:487–75.
50. Adams O, Weis J, Jasinska K, et al. Comparison of human metapneumovirus, respiratory syncytial virus and Rhinovirus respiratory tract infections in young children admitted to hospital. J Med Virol 2015;87:275–80.
51. Moe N, Krostad S, Stenseng IH, et al. Comparing human metapneumovirus and respiratory syncytial virus: viral co-detections, genotypes and risk factors for severe disease. PLoS One 2017;12:e0170200.
52. Yan XL, Li YN, Tang YJ, et al. Clinical characteristics and viral load of respiratory syncytial virus and human metapneumovirus in children hospitalized for acute lower respiratory tract infection. J Med Virol 2017;89:589–97.
53. Caracciolo S, Minini C, Colombrita D, et al. Human metapneumovirus infection in young children hospitalized with acute respiratory tract disease: virologic and clinical features. Pediatr Infect Dis J 2008;27:406–12.
54. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004;350:443–50.
55. Schuster JE, Khuri-Bulos N, Faouri S, et al. Impact of viral infections on severe acute respiratory illness as respiratory syncytial virus infections. Eur J Pediatr 2006;165:487–75.
56. Eskola J, Vaheri A, Dove W, et al. Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis. J Infect Dis 2005;191:382–6.